Verastem Shares Surge 51% After Pancreatic Cancer Treatment Study Data

Dow Jones05-24

By Ben Glickman

Shares of Verastem rose late Thursday after interim data from the company's trial evaluating a combination therapies to treat pancreatic cancer showed a high overall response rate.

The stock was up 51%, to $18.39, in post-market trading, after a 2.5% rise at the close. Shares are up about 50% this year as of the end of trading Thursday.

The Boston-based biopharmaceutical company said that in the dose level 1 cohort, there was an overall response rate of 83%, or five out of six. The company said there was one dose-limiting toxicity in that cohort.

Verastem said that of the 26 patients in all dosing cohorts who were able to have their first scan on treatment, 21 experienced a reduction of the change in target lesion sum of diameters.

The Phase 1/2 study is evaluating avutometinib plus defactinib in combination with gemcitabine and Nab-paclitaxel in patients with metastatic pancreatic cancer. The interim data will be presented at the American Society of Clinical Oncology annual meeting June 1.

Write to Ben Glickman at ben.glickman@wsj.com

(END) Dow Jones Newswires

May 23, 2024 18:47 ET (22:47 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2437474888?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-05-24 06:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2437474888","market":"hk","top_or_hot":-1,"title":"Verastem Shares Surge 51% After Pancreatic Cancer Treatment Study Data","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Ben Glickman \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/VSTM\">Verastem</a> rose late Thursday after interim data from the company's trial evaluating a combination therapies to treat pancreatic cancer showed a high overall response rate. \n</p>\n<p>\n  The stock was up 51%, to $18.39, in post-market trading, after a 2.5% rise at the close. Shares are up about 50% this year as of the end of trading Thursday. \n</p>\n<p>\n  The Boston-based biopharmaceutical company said that in the dose level 1 cohort, there was an overall response rate of 83%, or five out of six. The company said there was one dose-limiting toxicity in that cohort. \n</p>\n<p>\n  Verastem said that of the 26 patients in all dosing cohorts who were able to have their first scan on treatment, 21 experienced a reduction of the change in target lesion sum of diameters. \n</p>\n<p>\n  The Phase 1/2 study is evaluating avutometinib plus defactinib in combination with gemcitabine and Nab-paclitaxel in patients with metastatic pancreatic cancer. The interim data will be presented at the American Society of Clinical Oncology annual meeting June 1. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Ben Glickman at ben.glickman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 23, 2024 18:47 ET (22:47 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Verastem Shares Surge 51% After Pancreatic Cancer Treatment Study Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVerastem Shares Surge 51% After Pancreatic Cancer Treatment Study Data\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-24 06:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Ben Glickman \n\n\n \n\n\n  Shares of Verastem rose late Thursday after interim data from the company's trial evaluating a combination therapies to treat pancreatic cancer showed a high overall response ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VSTM","symbol_name":"Verastem","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2437474888","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2437474888","pubTimestamp":1716504420,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Verastem rose late Thursday after interim data from the company's trial evaluating a combination therapies to treat pancreatic cancer showed a high overall response rate.The stock was up 51%, to $18.39, in post-market trading, after a 2.5% rise at the close. Shares are up about 50% this year as of the end of trading Thursday.The Boston-based biopharmaceutical company said that in the dose level 1 cohort, there was an overall response rate of 83%, or five out of six. The company said there was one dose-limiting toxicity in that cohort.Verastem said that of the 26 patients in all dosing cohorts who were able to have their first scan on treatment, 21 experienced a reduction of the change in target lesion sum of diameters.The Phase 1/2 study is evaluating avutometinib plus defactinib in combination with gemcitabine and Nab-paclitaxel in patients with metastatic pancreatic cancer. The interim data will be presented at the American Society of Clinical Oncology annual meeting June 1","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VSTM":"Verastem","BK4139":"生物科技"},"translate_title":"胰腺癌治疗研究数据公布后，Verastem股价飙升51%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VSTM":1},"content_text":"By Ben Glickman \n\n\n \n\n\n  Shares of Verastem rose late Thursday after interim data from the company's trial evaluating a combination therapies to treat pancreatic cancer showed a high overall response rate. \n\n\n  The stock was up 51%, to $18.39, in post-market trading, after a 2.5% rise at the close. Shares are up about 50% this year as of the end of trading Thursday. \n\n\n  The Boston-based biopharmaceutical company said that in the dose level 1 cohort, there was an overall response rate of 83%, or five out of six. The company said there was one dose-limiting toxicity in that cohort. \n\n\n  Verastem said that of the 26 patients in all dosing cohorts who were able to have their first scan on treatment, 21 experienced a reduction of the change in target lesion sum of diameters. \n\n\n  The Phase 1/2 study is evaluating avutometinib plus defactinib in combination with gemcitabine and Nab-paclitaxel in patients with metastatic pancreatic cancer. The interim data will be presented at the American Society of Clinical Oncology annual meeting June 1. \n\n\n \n\n\n  Write to Ben Glickman at ben.glickman@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 23, 2024 18:47 ET (22:47 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.0","shortVersion":"4.24.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2437474888"}